Table 4.

Evaluation of combined incidences of mammary gland inflammation, neoplasia, non-neoplastic lesions, or lymph node effects at 14 months of age following prenatal exposure to bisphenol A (BPA), bisphenol AF (BPAF), or bisphenol S (BPS).

Lesion Incidence	Vehicle	BPA ($\mathrm{mg}/\mathrm{kg}$)			Vehicle	BPAF ($\mathrm{mg}/\mathrm{kg}$)			Vehicle	BPS ($\mathrm{mg}/\mathrm{kg}$)
	0	0.5	5	50	0	0.05	0.5	5	0	0.05	0.5	5
	$n=13$	$n=14$	$n=11$	$n=6$	$n=13$	$n=14$	$n=18$	$n=22$	$n=13$	$n=11$	$n=18$	$n=13$
Inflammation, all types	3 (0.156)	5 (0.385)	3 (0.590)	3 (0.257)	3 (0.062)	8 (0.079)	9 (0.126)	14 (0.023)*	3 (0.159)	4 (0.395)	15 (0.001)**	4 (0.500)
Neoplasia	0	0	0	0	0	0	0	0	0 (0.287)	0	2 (0.329)	1 (0.500)
Non-neoplastic lesions	0 (0.375)	3 (0.124)	2 (0.199)	1 (0.316)	0 ($<0.001$)‡	1 (0.518)	3 (0.182)	10 (0.004)**	0 (0.500)	1 (0.458)	7 (0.012)*	2 (0.240)
Lymph node, all	0	0	0	0	0 (0.076)	0	0	1 (0.629)	0 (0.287)	0	2 (0.329)	1 (0.500)

Note: p-values for dose–response trends are in parentheses in the Vehicle column; pairwise p-values are in the dose columns.

$n=\text{indicates}\text{number}\text{examined}$.

^*Differs from the control group by Fisher’s exact test at $p<0.05$;

^**$p<0.01$.

^‡Significant trend for BPAF by the Cochran-Armitage trend test at $p<0.01$.